Tell Psoriasis Patients When to Expect Peak Response to Cosentyx

Cosentyx (koe-SEN-tix, secukinumab) is a new monoclonal antibody for treating moderate to severe plaque psoriasis in adults.

It's the first to inhibit interleukin-17A (IL-17A).

Stelara (ustekinumab) inhibits IL-12 and IL-23...Enbrel (etanercept) and others block tumour necrosis factor.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote